A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
一项以生物标志物为导向的 2 期鲁索替尼研究表明,JAK/STAT 靶向治疗对 T 细胞淋巴瘤有效。
期刊:Blood
影响因子:23.1
doi:10.1182/blood.2021013379
Moskowitz, Alison J; Ghione, Paola; Jacobsen, Eric; Ruan, Jia; Schatz, Jonathan H; Noor, Sarah; Myskowski, Patricia; Vardhana, Santosha; Ganesan, Nivetha; Hancock, Helen; Davey, Theresa; Perez, Leslie; Ryu, Sunyoung; Santarosa, Alayna; Dowd, Jack; Obadi, Obadi; Pomerantz, Lauren; Yi, Nancy; Sohail, Samia; Galasso, Natasha; Neuman, Rachel; Liotta, Brielle; Blouin, William; Baik, Jeeyeon; Geyer, Mark B; Noy, Ariela; Straus, David; Kumar, Priyadarshini; Dogan, Ahmet; Hollmann, Travis; Drill, Esther; Rademaker, Jurgen; Schoder, Heiko; Inghirami, Giorgio; Weinstock, David M; Horwitz, Steven M